gemcitabine and oxaliplatin

Phase 2Small molecule

gemcitabine and oxaliplatin is one of 65 small molecule programs targeting Gallbladder Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gallbladder CarcinomaRecruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Non-Hodgkin LymphomaRecruiting

Gallbladder CarcinomaPhase 2

Recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

103 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

38 2

Rituxan

Oncovin

32 4

Polivy

Roche

Phase 3

22 5

Adriamycin

Pfizer

Phase 3

18 6

Gemzar

Johnson & Johnson

Phase 3

18 7

Oncovin

Eli Lilly

Phase 3

18 8

Gazyva

Roche

Phase 3

17 9

Cytoxan

BBaxter Healthcare Corporation

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04542824

PreclinicalActive, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04663347

Q3 2028

Phase 1Recruiting

Non-Hodgkin Lymphoma

NCT06447376

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

Completed·NNew Mexico Cancer Research Alliance·Phase 2·NCT00250822·11 enrolled

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Unknown status·SShanghai Jiao Tong University School of Medicine·N/A·NCT01125020·150 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

Active, not recruiting· Genmab logo

Genmab·Preclinical·NCT04542824·78 enrolled

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Active, not recruiting· Genmab logo

Genmab·Preclinical·NCT04663347·543 enrolled

Biliary Tract Cancer1 trial

A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Completed·SSoonchunhyang University Hospital·Phase 2·NCT00504192·40 enrolled

Pancreatic Cancer1 trial

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Withdrawn·UUniversity of Hawaii·Phase 2·NCT01524575

Gallbladder Carcinoma1 trial

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04183712·102 enrolled

3 more indications

Breast Cancer1 trial

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT00159458·7 enrolled

Chemotherapy1 trial

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Unknown status·SShi Ming·Phase 3·NCT03771846·188 enrolled

Non-Hodgkin Lymphoma1 trial

Pilot Safety-feasibility Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Recruiting·TTaylor Brooks·Phase 1·NCT06447376·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for gemcitabine and oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine and oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine and oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Genmab

gemcitabine and oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Diffuse Large B-Cell Lymphoma2 trials

Biliary Tract Cancer1 trial

Pancreatic Cancer1 trial

Gallbladder Carcinoma1 trial

Breast Cancer1 trial

Chemotherapy1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News